NCT04731909

Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer

Clinical Study of Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Third Military Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluates the effectiveness and safety of Toripalimab combined with Anlotinib and chemotherapy for the first-line treatment of ES-SCLC, and maintenance therapy are Toripalimab combined with Anlotinib.

Conditions

• SCLC, Extensive Stage
• Lung Cancer
• Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Toripalimab	Toripalimab 240mg,ivgtt,d1,q3w.
DRUG	Anlotinib	Anlotinib 12 mg/d,d1-14,q3w,4-6 cycles in total. In maintenance treatment period, Anlotinib 12 mg/d,d1,Oral for 2 weeks and stop for 1 week.
DRUG	Cisplatin	75mg/m2,d1,q3w,4-6 cycles in total.
DRUG	Carboplatin	AUC=5,d1,q3w,4-6 cycles in total.

Timeline

• Start date: 2018-10-01
• Primary completion: 2022-06-01
• Completion: 2023-06-30
• First posted: 2021-02-01
• Last updated: 2021-02-10

Locations

1 site across 1 country: China